



ARSEUS
Driving superior care

Press Release

Regulated information

EXERCISE OF WARRANTS INCREASES CAPITAL OF ARSEUS

Waregem (Belgium) / Rotterdam (Netherlands)¹, 13 June 2014 – Pursuant to Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, Arseus announces that 73,002 new shares have been issued as a result of the exercise of warrants. These newly issued shares are entitled to dividend as of the 2014 financial year.

The number of Arseus shares with voting rights is 31,431,360. The total number of voting rights (denominator) is 31,431,360. The share capital is € 322,111,645.98.

On 13 June 2014, there are 13,366 outstanding warrants under Warrant Plan 1. The total number of voting rights obtainable upon the exercise of these warrants is 13,366.

For more information:

Marieke Palstra

Director Investor Relations

+31 88 33 11 213 (Office)

marieke.palstra@arseus.com

Arseus profile

Arseus is a R&D scientific company delivering innovative solutions and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into three divisions: Fagron is global market leader in pharmaceutical compounding. Corilus develops and supplies unique integrated ICT solutions with substantial added value to medical specialists and is market leader in Belgium, France and the Netherlands. HL Technology develops and produces innovative precision components and orthopaedic tools for dental and medical professionals. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.

¹ This press release was sent out by Arseus NV and Arseus BV.